Evidence that camptothecin-induced aberrations in the G2 phase of cell cycle of Chinese hamster ovary (CHO) cell lines is associated with transcription

Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis

Volumn 452, Issue 2, 2000, Pages 189-195

  Mosesso, Pasquale ^a   Pichierri, Pietro ^a   Franchitto, Annapaola ^a   Palitti, Fabrizio ^a  

^a UNIVERSITY OF TUSCIA   (Italy)

Author keywords

Chromosomal aberrations; G2 phase of cell cycle; Inhibitors of DNA topoisomerase I; RNA synthesis

Indexed keywords

ALPHA AMANITIN; CAMPTOTHECIN; DNA TOPOISOMERASE INHIBITOR; DOUBLE STRANDED DNA; MESSENGER RNA PRECURSOR; RNA POLYMERASE;

ANIMAL CELL; ARTICLE; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL MUTANT; CHROMOSOME ABERRATION; CONTROLLED STUDY; DNA STRAND BREAKAGE; DNA SYNTHESIS; DRUG MECHANISM; GENETIC TRANSCRIPTION; GENOTOXICITY; NONHUMAN; PRIORITY JOURNAL; RNA SYNTHESIS;

AMANITINS; ANIMAL; CAMPTOTHECIN; CHO CELLS; CHROMOSOME ABERRATIONS; CRICETULUS; G2 PHASE; HAMSTERS; RNA, MESSENGER; TRANSCRIPTION, GENETIC;

EID: 0034683654     PISSN: 00275107     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0027-5107(00)00083-X     Document Type: Article

References (25)

1. Zwelling L.A., Michaels S., Erickson L.C., Ungerleider R.S., Nichols M., Kohn K.W. Protein-associated deoxyribonucleic acid intercalating agents 4′-(9-acridylamino)methanesulfon-m-anisidine and adriamycin. Biochemistry. 20:1981;6553-6563.
2. Zwelling L.A. DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Metastasis Rev. 4:1985;263-276.
3. Glisson R.C., Ross W.E. DNA topoisomerase II: a primer on the enzyme and its unique role as multidrug target in cancer chemotherapy. Pharmacol. Ther. 32:1987;89-106.
4. F. Palitti, F. Degrassi, C. Tanzarella, Inhibitors of DNA topoisomerases and chromosome aberrations, in: G. Obe, A.T. Natarajan (Eds.), Chromosomal Aberrations: Basis and Applied Aspects, Springer, Berlin, 1989, pp. 50-60.
5. Andersson H.C., Kihlman B.A. The production of chromosomal alterations in human lymphocytes by drugs known to interfere with the activity of DNA topoisomerase II m-AMSA. Carcinogenesis. 10:1989;123-130.
6. Degrassi F., De Salvia R., Tanzarella C., Palitti F. Induction of chromosomal aberrations and SCE by camptothecin, an inhibitor of mammalian topoisomerase I. Mutat. Res. 211:1989;125-130.
7. Dillehay L.E., Thompson L.H., Minkler J.L., Carrano A.V. The relationship between sister-chromatid exchange and perturbations in DNA replication in mutant EM9 and normal CHO cells. Mutat. Res. 109:1983;283-296.
8. D'Arpa P., Liu F.L. Topoisomerase-targeting antitumour drugs. Biochem. Biophys. Acta. 989:1989;163-177.
9. Hsiang Y.H., Lihou M.G., Liu L.F. Arrest of replication forks by drug-stabilised topoisomerase I-DNA cleavable complexes as a mechanism of cell killing by camptothecin. Cancer Res. 49:1989;5077-5082.
10. Zhang H., D'Arpa P., Liu L.F. A model for tumour cell killing by topoisomerase poisons. Cancer Cells. 2:1990;23-27.
11. Ryan A.J., Squires S., Strutt H.L., Johnson R.T. Camptothecin cytotoxicity in mammalian cells is associated with the induction of persistent double-strand breaks in replicating DNA. Nucleic Acids Res. 19:1991;3295-3300.
12. Degrassi F., De Salvia R., Tanzarella C., Palitti F. Induction of chromosomal aberrations and SCE by camptothecin, an inhibitor of mammalian topoisomerase I. Mutat. Res. 211:1989;125-130.
13. Palitti F. Mechanism of induction of chromosomal aberrations by inhibitors of DNA topoisomerases. Environ. Mol. Mutagen. 22:1993;275-277.
14. Andersson H.C., Kihlman B.A. Induction of chromosomal aberrations by camptothecin in root-tip cells of Vicia faba. Mutat. Res. 268:1992;168-181.
15. F. Palitti, P. Mosesso, D. Di Chiara, A. Schinoppi, M. Fiore, L. Bassi, Use of antitopoisomerase drugs to study the mechanisms of induction of chromosomal damage, in: G. Obe, A.T. Natarajan (Eds.), Chromosomal Alterations, Springer, Berlin, 1994, pp. 103-115.
16. 2 phases of the cell cycle. Mutagenesis. 13:1998;257-261.
17. 0 human lymphocytes. Mutagenesis. 14:1999;103-105.
18. Barrows L.R., Holden J.A., Anderson M., D'Arpa P. The CHO XRCC1 mutant, EM9, deficient in DNA ligase III activity, exhibits hypersensitivity to camptothecin independent of DNA replication. Mutat. Res. 408:1998;103-110.
19. Savage J.R. Application of chromosome banding techniques to the study of primary chromosome structural changes. J. Med. Genet. 14:1977;362-370.
20. Zanotti G., Petersen G., Wieland T. Structure-toxicity relationships in the amatoxin series. Structural variations of side chain 3 and inhibition of RNA polymerase II. Int. J. Pept. Protein Res. 40:1992;551-558.
21. Christians F.C., Hanawalt P.C. Inhibition of transcription and strand-specific DNA repair by alpha-amanitin in Chinese hamster ovary cells. Mutat. Res. 274:1992;93-101.
22. 2 sensitivity to the induction of chromosomal damage in the CHO mutant EM9 than in its parental line AA8 by camptothecin, an inhibitor of DNA topoisomerase I. Mutat. Res. 285:1993;281-285.
23. Voigt W., Matsui S., Yin M.B., Burhans W.C., Minderman H., Rustum Y.M. Topoisomerase-I inhibitor SN-38 can induce DNA damage and chromosomal aberration independent from DNA synthesis. Anticancer Res. 18:1998;3499-3505.
24. Barrows L.R., Paxton M.B., Kennedy K.A., Thompson L.H. XRCC1 gene expression and phenotypes of revertant EM9 (CHO) cell lines. Carcinogenesis. 12:1991;805-811.
25. Silber R., Degar B., Costin D., Newcomb E.W., Mani M., Rosenberg C.R., Morse L., Drygas J.C., Canellakis Z.N., Potmesil M. Chemosensitivity of lymphocytes from patients with B cell chronic lymphocytic leukemia to chlorambucil, fludarabine, and camptothecin analogs. Blood. 84:1994;3440-3446.